Acousia Therapeutics Launches PROHEAR-Study with First Patient Enrolled

Tübingen (Germany) – Acousia Therapeutics GmbH, a Golgi Neurosciences’ portfolio company focused on hearing loss solutions, has achieved a significant milestone by enrolling the first patient in its PROHEAR-Study, a Phase 2a clinical trial. This study is set to explore the potential of ACOU085, a groundbreaking therapy aimed at preventing hearing loss induced by cisplatin, a common chemotherapy drug.

Cisplatin-induced hearing loss is a severe and prevalent side effect for cancer patients, profoundly affecting their quality of life. The PROHEAR-Study represents a critical step forward in addressing this unmet medical need.

For more information please visit Acousia Therapeutics or Golgi Neurosciences’ Linkedin Page.